Rabies immunoglobulin (RIg) is one component of the post-exposure prophylaxis for people who may have been exposed to rabies virus or other lyssaviruses. RIg is in short supply globally and Australia has exhausted its supply of Imogam, the registered human RIg product.
 
An alternative human RIg product, KamRAB, has been sourced for use in Australia. KamRAB is not registered for use in Australia. It is approved under section 19A of the Therapeutic Goods Act 1989 until 31 January 2021.
https://www.tga.gov.au/accessing-medicines-during-medicines-shortage.   
 
The fact sheet for general practitioners and fact sheet for patients provide information about KamRAB and explain the risks and benefits.
 
Immunisation providers should phone their local public health unit on 1300 066 055 for advice on post-exposure prophylaxis and to order Rig and rabies vaccine for patients who may have been exposed to rabies virus or other lyssaviruses.
 
More information about rabies and other lyssaviruses is available in the Australian Immunisation Handbook​
Page Updated: Friday 8 November 2019
Contact page owner: Immunisation